BR112016017087A2 - forma cristalina alfa do composto monobenzoato a e seu método de preparação e composição farmacêutica compreendendo-a - Google Patents
forma cristalina alfa do composto monobenzoato a e seu método de preparação e composição farmacêutica compreendendo-aInfo
- Publication number
- BR112016017087A2 BR112016017087A2 BR112016017087A BR112016017087A BR112016017087A2 BR 112016017087 A2 BR112016017087 A2 BR 112016017087A2 BR 112016017087 A BR112016017087 A BR 112016017087A BR 112016017087 A BR112016017087 A BR 112016017087A BR 112016017087 A2 BR112016017087 A2 BR 112016017087A2
- Authority
- BR
- Brazil
- Prior art keywords
- monobenzoate
- compound
- preparation
- pharmaceutical composition
- crystalline form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410037009 | 2014-01-24 | ||
| CN201410037009.X | 2014-01-24 | ||
| PCT/CN2015/071525 WO2015110077A1 (zh) | 2014-01-24 | 2015-01-26 | 化合物A单苯甲酸盐的晶型α及其制备方法和含有该晶型的药物组合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112016017087A2 true BR112016017087A2 (pt) | 2017-08-08 |
| BR112016017087A8 BR112016017087A8 (pt) | 2018-04-17 |
| BR112016017087B1 BR112016017087B1 (pt) | 2022-12-27 |
Family
ID=53680849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016017087-3A BR112016017087B1 (pt) | 2014-01-24 | 2015-01-26 | Forma cristalina alfa do composto monobenzoato a, seu método de preparação, e composição farmacêutica |
Country Status (5)
| Country | Link |
|---|---|
| CN (1) | CN104803971B (pt) |
| BR (1) | BR112016017087B1 (pt) |
| MX (1) | MX366651B (pt) |
| RU (1) | RU2677660C2 (pt) |
| WO (1) | WO2015110077A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106349215B (zh) * | 2015-07-15 | 2022-02-08 | 深圳信立泰药业股份有限公司 | 一种化合物a苯甲酸盐的无定形及其制备方法和含有该无定形的药物组合物 |
| CN106349216B (zh) * | 2015-07-15 | 2020-09-11 | 深圳信立泰药业股份有限公司 | 化合物A的晶型α及其制备方法和含有该晶型的药物组合物 |
| WO2018219295A1 (zh) * | 2017-05-31 | 2018-12-06 | 深圳信立泰药业股份有限公司 | 二肽基肽酶iv抑制剂的氘代1,2,4-三嗪衍生物 |
| CN109692164A (zh) * | 2017-10-20 | 2019-04-30 | 深圳信立泰药业股份有限公司 | 化合物a或其盐的药物组合物及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2805953B1 (en) * | 2004-12-21 | 2016-03-09 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
| CA2622642C (en) * | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| FR2933979B1 (fr) * | 2008-07-15 | 2012-08-24 | Pf Medicament | Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine |
| CN102791701B (zh) * | 2009-12-30 | 2014-02-12 | 深圳信立泰药业股份有限公司 | 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物 |
| BR112012028906A2 (pt) * | 2010-05-12 | 2016-07-26 | Mapi Pharma Ltd | polimorfos de benzoato de alogliptina |
| CN103172615A (zh) * | 2013-03-29 | 2013-06-26 | 山东罗欣药业股份有限公司 | 苯甲酸阿格列汀晶型化合物 |
-
2015
- 2015-01-23 CN CN201510033908.7A patent/CN104803971B/zh active Active
- 2015-01-26 BR BR112016017087-3A patent/BR112016017087B1/pt active IP Right Grant
- 2015-01-26 RU RU2016134404A patent/RU2677660C2/ru active
- 2015-01-26 MX MX2016009667A patent/MX366651B/es active IP Right Grant
- 2015-01-26 WO PCT/CN2015/071525 patent/WO2015110077A1/zh active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016017087B1 (pt) | 2022-12-27 |
| CN104803971A (zh) | 2015-07-29 |
| BR112016017087A8 (pt) | 2018-04-17 |
| WO2015110077A1 (zh) | 2015-07-30 |
| MX366651B (es) | 2019-07-17 |
| RU2677660C2 (ru) | 2019-01-18 |
| RU2016134404A (ru) | 2018-03-01 |
| MX2016009667A (es) | 2017-02-28 |
| RU2016134404A3 (pt) | 2018-08-15 |
| CN104803971B (zh) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252477A0 (en) | 2-aminopyrimidine compound, pharmaceutical structure and its use | |
| DK3175132T3 (da) | Befæstelseselementer | |
| DK2918305T3 (da) | Forskudt kateterfastgørelsesindretning | |
| SG10201506638WA (en) | Fabrication of nanowire structures | |
| BR112016021011A2 (pt) | composição tópica e usos de um composto | |
| PL3685682T3 (pl) | Doustna kompozycja nawadniająca | |
| EP3166617C0 (en) | POLOXAMER COMPOSITION FREE FROM LONG CIRCULATION MATERIAL, METHODS OF PREPARATION AND USES | |
| PT3202759T (pt) | Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo | |
| EP3214078A4 (en) | 3-arylbenzofuranone compound and composition formed therefrom | |
| DK3134483T3 (da) | Vandig sammensætning med forbedret brudforlængelse | |
| BR112016017087A2 (pt) | forma cristalina alfa do composto monobenzoato a e seu método de preparação e composição farmacêutica compreendendo-a | |
| LT3189045T (lt) | Naujos nilotinibo druskos ir jų polimorfai | |
| ZA201700843B (en) | Oral pharmaceutical composition of isotretinoin | |
| KR20180084728A (ko) | 구강용 조성물 | |
| DK3089740T3 (da) | Farmaceutisk sammensætning | |
| MA41255A (fr) | Composition de composé salicylate | |
| FR3020371B1 (fr) | Composition thermoplastique | |
| GB201621771D0 (en) | New salts of compounds and uses thereof | |
| TH1601000318A (th) | สารประกอบเเละวิธีการเพื่อการสะสมเเร่ธาตุทางทันตกรรม | |
| TH1601002230B (th) | องค์ประกอบของยาสีฟัน | |
| TH1501005357A (th) | สารประกอบพิแรโซล-เอไมด์ และการใช้ทางการแพทย์ของมัน | |
| TH1601003496A (th) | องค์ประกอบที่มีปริมาณของสารประกอบประเภทเซซามินสูง | |
| TH1501006535A (th) | องค์ประกอบสำหรับการเตรียมกรดเทเรฟธาลิก | |
| TH1501005593A (th) | องค์ประกอบของยาปฏิชีวนะเซฟโทโลเซน | |
| TH1501006442A (th) | รูปดัดแปรผลึกของอีโลไบซิแบต |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/01/2015, OBSERVADAS AS CONDICOES LEGAIS |
|
| B25A | Requested transfer of rights approved |
Owner name: FOCHON PHARMACEUTICALS, LTD. (CN) |